AKRO vs. SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, BPMC, and VRNA
Should you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry.
Akero Therapeutics vs. Its Competitors
Summit Therapeutics (NASDAQ:SMMT) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.
In the previous week, Summit Therapeutics had 13 more articles in the media than Akero Therapeutics. MarketBeat recorded 15 mentions for Summit Therapeutics and 2 mentions for Akero Therapeutics. Akero Therapeutics' average media sentiment score of 0.93 beat Summit Therapeutics' score of 0.62 indicating that Akero Therapeutics is being referred to more favorably in the news media.
4.6% of Summit Therapeutics shares are held by institutional investors. 84.9% of Summit Therapeutics shares are held by company insiders. Comparatively, 7.1% of Akero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summit Therapeutics has a beta of -1.01, indicating that its share price is 201% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.15, indicating that its share price is 115% less volatile than the S&P 500.
Summit Therapeutics presently has a consensus price target of $34.67, suggesting a potential upside of 53.26%. Akero Therapeutics has a consensus price target of $82.50, suggesting a potential upside of 59.02%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akero Therapeutics is more favorable than Summit Therapeutics.
Summit Therapeutics has higher revenue and earnings than Akero Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Akero Therapeutics' return on equity of -15.19% beat Summit Therapeutics' return on equity.
Summary
Summit Therapeutics beats Akero Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Akero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AKRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akero Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AKRO) was last updated on 7/3/2025 by MarketBeat.com Staff
Free AKRO Stock Alerts